When is Tivicay's Patent Expiring?
Tivicay, also known by its generic name dolutegravir, has patent protection that influences its market availability. Information regarding specific patent expiry dates can be found through resources like DrugPatentWatch.com [1].
What is Dolutegravir Used For?
Dolutegravir is an integrase inhibitor used in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV) type 1 infection [2].
Are There Generics of Tivicay Available Now?
The availability of generic versions of Tivicay depends on the expiration of its patents and any associated exclusivity periods. Typically, once patents expire, other companies can seek approval to market generic versions of the drug [1].
How Does Dolutegravir Work?
Dolutegravir works by blocking the action of an enzyme called integrase, which HIV needs to multiply. By inhibiting integrase, dolutegravir prevents the virus from integrating its genetic material into the host cell's DNA, thereby stopping viral replication [3].
What Are the Side Effects of Dolutegravir?
Common side effects of dolutegravir can include insomnia, headache, abnormal dreams, nausea, and diarrhea. More serious, though less common, side effects have also been reported [2].
What Happens If a Generic Version Becomes Available?
When generic versions of a drug become available, they typically lead to lower prices due to increased competition. This can improve access for patients and healthcare systems [1].
Are There Other Integrase Inhibitors for HIV Treatment?
Yes, other integrase inhibitors are available for HIV treatment. Examples include bictegravir, raltegravir, and elvitegravir, which are often used in combination therapies [4].
Sources
1. DrugPatentWatch.com.
2. National Institutes of Health. (n.d.). Dolutegravir. Retrieved from https://medlineplus.gov/druginfo/meds/a614057.html
3. FDA Drug Approvals and Databases. (n.d.). Tivicay. Retrieved from https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/tivicay-dolutegravir-information
4. Centers for Disease Control and Prevention. (n.d.). HIV Treatment: Antiretroviral Therapy. Retrieved from https://www.cdc.gov/hiv/basics/treatment.html